Recombinant Human CDH17/Cadherin 17 Domain 7 Protein
Beta LifeScience
SKU/CAT #: BLK-00300P-100UG

Human CDH17 Domain 7 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human CDH17/Cadherin 17 Domain 7 Protein
Beta LifeScience
SKU/CAT #: BLK-00300P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human CDH17/Cadherin 17 Domain 7 Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Ala668-Gly777. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | Q12864 |
Target Symbol | CDH17/Cadherin 17 Domain 7 |
Species | Human |
Expression System | HEK293 |
Tag | C-hFc |
Expression Range | Ala668-Gly777 |
Mol. Weight | The protein has a predicted MW of 38.42 kDa. Due to glycosylation, the protein migrates to 48-52 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22 um filtered solution in 20mM Tris, 150mM NaCl (pH 8.0). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Liver-intestine cadherin (CDH17) has been known to function as a tumor stimulator and diagnostic marker for almost two decades.In vivo studies showed CDH17 knockout resulted in apoptotic PC tumor death through activating caspase-3 activity. Taken together, CDH17 functions as an oncogenic molecule critical to PC growth by regulating tumor apoptosis signaling pathways and CDH17 could be targeted to develop an anti-PC therapeutic approach. |